Pharmaceuticals

Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

- Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population - In the overall p...

2021-12-09 08:38 3689

Servatus raises $7.5 million to advance autoimmune therapies with its microbial biotherapeutics clinical programs

* Servatus has raised $7.5 million in an oversubscribed capital raise, with strong support from sophisticated shareholders * Funds raised will underpin Servatus' live microbial and engineered protein biotherapeutics drug development * Two Phase 1/2 clinical trials to launch shortly in Queens...

2021-12-09 07:35 3731

Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China

The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, through a randomized, double-blind and placebo-controlled trial Brii Bio is also seeking U.S. FDA Emergency Use Authorization for the amubarvimab/romlusevimab combination DURHAM, N.C. and ...

2021-12-09 06:10 4493

China's Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, GenScript ProBio Expanding Manufacturing Capacity Again

NANJING, China, Dec. 8, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio at the opening ceremony announced thatthe largest commercial GMP plasmid manufacturing facility in ...

2021-12-08 18:22 3841

SHL Medical Publishes its Molly Modular Autoinjector Platform Technology White Paper

ZUG, Switzerland, Dec. 8, 2021 /PRNewswire/ -- SHL Medical, a world-leading solutions provider in the design, development, and manufacturing of self-injection devices, announced the publication of its white paper titled, "Molly® Autoinjector: A Systematic Review of Molly's Integrated and Flexible...

2021-12-08 14:00 5420

Henlius' Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first interim analysis met the primary study endpoint of the overall survival (OS) of the Phase 3 clinical study (NCT04063163) of its innovative PD-1 inhibitor serplulimab in combination with chemot...

2021-12-08 08:30 4266

Sino Biological newly launched a panel of research reagents for SARS-CoV-2 Omicron variant

BEIJING, China, Dec. 7, 2021 /PRNewswire/ -- Sino Biological, Inc. ( http://www.sinobiological.com ; SHE: 301047) announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-COV-2 virus, which qu...

2021-12-07 18:18 6375

Overland Pharmaceuticals Partners with ArisGlobal to Accelerate Safety Capabilities

Premier pharmaceutical company adopts LifeSphere Multivigilance to centralize pharmacovigilance activities MIAMI, Dec. 7, 2021 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end drug development technology platform ...

2021-12-07 17:13 3146

Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021

SAN FRANCISCO and SUZHOU, China, Dec. 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major dis...

2021-12-07 08:00 4488

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

BEIJING and BRIDGEWATER, N.J., Dec. 7, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the...

2021-12-07 05:54 4363

RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations

Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants of conce...

2021-12-06 20:01 5126

Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies

HOUSTON and SINGAPORE, Dec. 6, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, and Cancer Research UK, the world's leading cancer charity, today annou...

2021-12-06 17:30 2152

Odyssey Announces Agreement to Combine with BenevolentAI

LONDON and AMSTERDAM, Dec. 6, 2021 /PRNewswire/ -- Odyssey Acquisition S.A. ("Odyssey"), a Euronext Amsterdam-listed special-purpose acquisition company, and BenevolentAI, a leading clinical-stage AI drug discovery company, today announced that they have entered into a definitive agreement for a ...

2021-12-06 14:00 3168

Brii Biosciences Included in Hong Kong Stock Connect

DURHAM, N.C. and BEIJING, Dec. 6, 2021 /PRNewswire/ -- Brii Biosciences  Limited ("Brii Bio" or the "Company", stock code: 2137.HK), today announced that the Company has been added to the Hong Kong Stock Connect. This inclusion allows eligible domestic investors...

2021-12-06 10:54 5200

Henlius' 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration

SHANGHAI, Dec. 4, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that bevacizumab biosimilar Hanbeitai, developed and manufactured by Henlius independently, has been approved by the National Medical Products Administration (NMPA). It is indicated for the treatment of meta...

2021-12-04 01:51 7266

Mongolian Government To Build On COVID-19 Vaccine And Booster Success

* Mongolia secures nearly 70% vaccination rates and an overall casualty rate of only 0.3% * Successes against COVID-19 position country well for ambitious and progressive reforms as part of government's Vision 2050 agenda ULAANBAATAR, Mongolia, Dec. 3, 2021 /PRNewswire/ -- Mongolia is prepari...

2021-12-03 15:00 3331

RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment

YANTAI, China, Dec. 3, 2021 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, today announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept (RC18) for treating systemic lupus erythematosus (SLE) and a novel antibody-dru...

2021-12-03 13:45 6431

Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications

SAN FRANCISCO, INDIANAPOLIS, and SUZHOU, China, Dec. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and ...

2021-12-03 12:37 5432

Ascletis Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-oral Direct Anti-HCV Therapy

HANGZHOU, China and SHAOXING, China, Dec. 3, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/ GANOVO® (Danoprevir) regimen has been included in the Medicine Catalog for National Basic Medical Insu...

2021-12-03 12:05 6024

Decode Genetics Publishes the Largest Ever Study of the Plasma Proteome

REYKJAVIK, Iceland, Dec. 3, 2021 /PRNewswire/ -- In a study published today in Nature genetics, scientists at deCODE genetics , a subsidiary of the pharmaceutical company Amgen, demonstrate how measuring the levels of a large number of proteins in plasma at population scale when combined with dat...

2021-12-03 03:26 4223
1 ... 173174175176177178179 ... 184

Week's Top Stories